> Details

Seiler, Lisa K. [Author]; Phung, Ngoc Linh [Author]; Nikolin, Christoph [Author]; Immenschuh, Stephan [Author]; Erck, Christian [Author]; Kaufeld, Jessica [Author]; Haller, Hermann [Author]; Falk, Christine S. [Author]; Jonczyk, Rebecca [Author]; Lindner, Patrick [Author]; Thoms, Stefanie [Author]; Siegl, Julia [Author]; Mayer, Günter [Author]; Feederle, Regina [Author]; Blume, Cornelia A. [Author]

An Antibody-Aptamer-Hybrid Lateral Flow Assay for Detection of CXCL9 in Antibody-Mediated Rejection after Kidney Transplantation - [published Version]

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: Text; E-Article
  • Title: An Antibody-Aptamer-Hybrid Lateral Flow Assay for Detection of CXCL9 in Antibody-Mediated Rejection after Kidney Transplantation
  • Contributor: Seiler, Lisa K. [Author]; Phung, Ngoc Linh [Author]; Nikolin, Christoph [Author]; Immenschuh, Stephan [Author]; Erck, Christian [Author]; Kaufeld, Jessica [Author]; Haller, Hermann [Author]; Falk, Christine S. [Author]; Jonczyk, Rebecca [Author]; Lindner, Patrick [Author]; Thoms, Stefanie [Author]; Siegl, Julia [Author]; Mayer, Günter [Author]; Feederle, Regina [Author]; Blume, Cornelia A. [Author]
  • imprint: Basel : MDPI, 2022
  • Published in: Diagnostics : open access journal 12 (2022), Nr. 2 ; Diagnostics : open access journal
  • Issue: published Version
  • Language: English
  • DOI: https://doi.org/10.15488/12230; https://doi.org/10.3390/diagnostics12020308
  • Keywords: neural net analysis ; aptamer-antibody-hybrid lateral flow assay (hybrid-LFA) ; biomarkers ; CXCL9 (MIG) ; aptamer ; antibody-mediated rejection (AMR) ; antibody
  • Origination:
  • Footnote: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Description: Chronic antibody-mediated rejection (AMR) is a key limiting factor for the clinical outcome of a kidney transplantation (Ktx), where early diagnosis and therapeutic intervention is needed. This study describes the identification of the biomarker CXC-motif chemokine ligand (CXCL) 9 as an indicator for AMR and presents a new aptamer-antibody-hybrid lateral flow assay (hybrid-LFA) for detection in urine. Biomarker evaluation included two independent cohorts of kidney transplant recipients (KTRs) from a protocol biopsy program and used subgroup comparisons according to BANFF-classifications. Plasma, urine and biopsy lysate samples were analyzed with a Luminex-based multiplex assay. The CXCL9-specific hybrid-LFA was developed based upon a specific rat antibody immobilized on a nitrocellulose-membrane and the coupling of a CXCL9-binding aptamer to gold nanoparticles. LFA performance was assessed according to receiver operating characteristic (ROC) analysis. Among 15 high-scored biomarkers according to a neural network analysis, significantly higher levels of CXCL9 were found in plasma and urine and biopsy lysates of KTRs with biopsy-proven AMR. The newly developed hybrid-LFA reached a sensitivity and specificity of 71% and an AUC of 0.79 for CXCL9. This point-of-care-test (POCT) improves early diagnosis-making in AMR after Ktx, especially in KTRs with undetermined status of donor-specific HLA-antibodies.
  • Access State: Open Access
  • Rights information: Attribution (CC BY)